View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
Haselmeier|2 May 2019

i-pen² Variable-dose Injection Device

The i-pen2 is an injection device, designed for 3ml cartridges.

The i-pen2 is an injection device, designed for 3ml cartridges.

It is reusable and injects variable doses. The pen is also colour-customisable and has a sleek appearance with a cost-effective design, chosen through extensive patient-testing.

The i-pen2 was specifically designed for self-injecting patients and has flexible customisation options to cover all needs. The pen is of high-quality but is also economic.


  • A plastic reusable pen, designed through patient-testing
  • Its dose increments range from 0.01ml to 0.6ml
  • It is easy-to-use and doses can be altered safely
  • The dose indicator is easy-to-read to reassure the patient
  • It is of high-quality but also economic

Applications of the i-pen2 include:

  • INSUPen® EZ followed Biocon’s INSUPen®. Biocon holds distribution rights for the pen and it is used with Basalog™ and Insugen™ insulin, as well as insulin analogues. It is reusable and based on Haselmeier’s i-pen². Its design means it is easy-to-use, delivering doses ranging from 0.01ml to 0.60ml. It also makes a sound when changing doses, ensuring accuracy and reliability. INSUPen® EZ is available in four different colours for organisation.

Type 2 diabetes is a global health problem. According to expert estimates, the number of patients worldwide will increase by 48% by 2045.
The D-Flex injection pen can do more than previous pens. D-Flex can be configured for several fixed-dose values and is thus a variable fixed-dose pen.
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy


Thank you for subscribing to Pharmaceutical Technology